Global Markets Direct’s, ‘Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Review, H2 2016’, provides in depth analysis on Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted pipeline therapeutics.
The report provides comprehensive information on the Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation.
- The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - The report reviews Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics and enlists all their major and minor projects - The report assesses Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
The Alzheimer’s disease diagnostics and therapeutics market was valued at USD 6,632.82 million in 2020, and it is expected to reach approximately USD 9,073 million in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026. The study titled, "Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a...
The global dementia drugs market was valued at approximately USD 12,736.06 million in 2020 and is expected to witness a revenue of USD 19,655.10 million in 2026, with a CAGR of 7.87% over the forecast period. The outbreak of the COVID-19 pandemic is expected to have a significant impact on the Dementia drugs market. According to a research...
Down Syndrome (Genetic Disorders) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Down Syndrome - Drugs in Development, 2021, provides an overview of the Down Syndrome (Genetic Disorders) pipeline landscape. Down syndrome is a genetic disorder...
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021 Summary Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 17 molecules. Out...
531 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• May 2021
Globally Pharmaceutical markets are showing rapid growth and in coming years expected to evolve further in the field of research and development, manufacturing, and formulation due to rise in population, increase in chronic diseases like infectious diseases, oncology, cardiovascular disorders, rising healthcare expenditures, collaborations,...
The pharmaceutical intermediate market was valued at US$ 27,356.70 million in 2020 and is projected to reach US$ 37,290.33 million by 2028; it is expected to grow at a CAGR of 4.2% from 2021 to 2028. The rising prevalence of chronic diseases and infectious diseases, and escalating investment by pharmaceutical companies in R&D activities...
The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right...
120 pages •
By Infiniti Research Limited
• Apr 2021
Global Air Particle Monitor System Market 2021-2025 The analyst has been monitoring the air particle monitor system market and it is poised to grow by $ 1.74 bn during 2021-2025, progressing at a CAGR of almost 7% during the forecast period. Our report on air particle monitor system market provides a holistic analysis,...
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2021 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets. The report provides a detailed understanding and analysis of how and why companies enter business, product,...
576 pages •
By Global Industry Analysts
• Apr 2021
- With the World Awaiting Vaccine Supply for 7.5 Billion People, the Drug Packaging Market Remains Optimistic With a 13.2% Spike in Revenues
- The global market for Pharmaceutical Packaging Equipment is expected to witness a 13.2% spurt in revenues for the year 2020 and thereafter reach US$15.2 billion by...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.